ICH
ICH Q10 3.2.2
3. CONTINUAL IMPROVEMENT OF PROCESS PERFORMANCE AND PRODUCT QUALITY
조항 원문
Corrective Action and Preventive Action (CAPA) System The pharmaceutical company should have a system for implementing corrective actions and preventive actions resulting from the investigation of complaints, product rejections, non-conformances, recalls, deviations, audits, regulatory inspections and findings, and trends from process performance and product quality monitoring. A structured approach to the investigation process should be used with the objective of determining the root cause. The level of effort, formality, and documentation of the investigation should be commensurate with the level of risk, in line with ICH Q9. CAPA methodology should result in product and process improvements and enhanced product and process understanding.
Table II: Application of Corrective Action and Preventive Action System throughout the Product Lifecycle
Pharmaceutical Technology Commercial Product Development Transfer Manufacturing Discontinuation
Product or process CAPA can be used as CAPA should be used CAPA should continue variability is explored. an effective system and the effectiveness after the product is CAPA methodology is for feedback, of the actions should discontinued. The useful where corrective feedforward and be evaluated. impact on product actions and preventive continual remaining on the actions are improvement. market should be incorporated into the considered as well as iterative design and other products which development process. might be impacted.
본문은 원문(영어)입니다. 국문 번역은 준비 중입니다.
이 조항을 근거로 든 용어
출처: International Council for Harmonisation (ICH) · © ICH. Per the legal notice in each guideline, the document may be used, reproduced and distributed provided ICH's copyright is acknowledged; any adaptation or translation must be labelled as such and must not imply ICH endorsement. · 수집일 2026-11-15